MGMT and glioblastoma: The dose expansion or phase 2 study enrolled up to four cohorts: recently detected unmethylated GBM patients in arm A as well as arm B, and cohorts of patients bearing recurrent/refractory GBM divided via MGMT status (unmethylated/methylated) within arm C. Patients of arms A or B have been treated till their RT is completed, while patients in arm C could undergo treatment if there are no safety concerns or tumor growth.